Arbutus Biopharma Corporation announced fourth quarter and year-end 2025 financial results, reporting net loss of $33.5 million or $0.17 per share, revenue of $14.1 million, and cash of $91.5 million as of December 31, 2025. Highlights include a $2.25 billion Moderna settlement and two additional functional cures in imdusiran Phase 2a trials, bolstering financial position and clinical progress.
Key takeaways
Moderna settlement: $950 million upfront payment in July 2026 plus $1.3 billion contingent; Arbutus entitled to 20% of noncontingent payment after costs and owns 16% of Genevant.
Two additional patients from Phase 2a imdusiran trials achieved functional cure, totaling 10 patients.
Cash, cash equivalents and marketable securities: $91.5 million as of December 31, 2025 (vs. $122.6 million as of December 31, 2024).
FY2025 total revenue: $14.1 million (vs. $6.2 million in 2024).
FY2025 net loss: $33.5 million or $0.17 per basic and diluted share (vs. $69.9 million or $0.38 per share in 2024).
$0.5 million milestone payment received from Alnylam in January 2026 for LNP use in HCC product candidate.